Latest Alkylating antineoplastic agents Stories
- Data support VAL-083's importance as a potential therapy for non-small cell lung cancer (NSCLC), including drug-resistant NSCLC - VANCOUVER, British Columbia and MENLO PARK, Calif.,
SAN DIEGO, Feb.
- ABRAXANE plus gemcitabine to be PBS listed for Australian patients with metastatic pancreatic cancer from 1 November MELBOURNE, Australia, Oct.
DelMar Pharmaceuticals Presents Data at AACR's New Horizons in Cancer Research Conference in Shanghai, China VANCOUVER, British Columbia, MENLO PARK, Calif. and SHANGHAI, Oct.
LifeScienceIndustryResearch.com adds latest Report on “Global and Chinese Cisplatin (CAS 15663-27-1) Industry, 2009-2019 Market Research Report” to its store.
The new combination agent TAS-102 is able to improve overall survival compared to placebo in patients whose metastatic colorectal cancer is refractory to standard therapies.
Proof-of-Concept Trial Targets DNA Repair in Bile Duct Cancers SAN DIEGO and NEW TAIPEI CITY, Taiwan, June 17, 2014 /PRNewswire-iReach/ -- Senhwa Biosciences, Inc.
-- Difficult-to-treat squamous NSCLC patients saw clinical benefit with necitumumab plus chemotherapy regimen -- INDIANAPOLIS, May 14, 2014 /PRNewswire/ -- Lung cancer patients with
FLINT, Mich., April 22, 2014 /PRNewswire-iReach/ -- The US Food and Drug Administration has announced the expanded approval of Arzerra(®) (ofatumumab) in combination with chlorambucil for